Sample classification was based on expression levels for both MLH1 and MSH2: samples with lower expression in tumour vs normal tissue for both genes were considered as MMR deficient, all other samples were designated MMR proficient (including patients with higher or similar expression in tumour vs. normal tissue). This evidence concerns the gene MRC1 and neoplasm.